Liraglutide vs Tirzepatide: Head-to-Head Comparison
Liraglutide was the first GLP-1 agonist approved for obesity, producing ~8% weight loss with daily dosing. Tirzepatide is a newer dual GIP/GLP-1 agonist achieving up to 22.5% weight loss with weekly dosing. Tirzepatide is significantly more effective but liraglutide has a longer safety track record.
Side-by-Side Comparison
| Dimension | Liraglutide | Tirzepatide |
|---|---|---|
| Evidence Level | Level A — 10+ years of clinical data (SCALE, LEADER) | Level A — large Phase 3 programs (SURMOUNT, SURPASS) |
| FDA Status | Approved for T2D (Victoza) and obesity (Saxenda) | Approved for T2D (Mounjaro) and obesity (Zepbound) |
| Weight Loss Efficacy | ~8% mean body weight loss (Saxenda 3.0 mg) | Up to 22.5% mean body weight loss (Zepbound 15 mg) |
| Dosing Convenience | Daily subcutaneous injection | Once weekly subcutaneous injection |
| Mechanism | GLP-1 receptor agonist only | Dual GIP + GLP-1 receptor agonist |
| Long-Term Safety | 10+ years of real-world data; well-established profile | Newer agent; ~3 years post-approval data |
Peptide Overviews
Liraglutide
AFDA ApprovedLiraglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It was the first GLP-1 agonist approved specifically for obesity.
Tirzepatide
AFDA ApprovedTirzepatide is the first dual GIP and GLP-1 receptor agonist, approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Achieves unprecedented weight loss in clinical trials.
Liraglutide vs Tirzepatide: FAQ
Stay Informed on Peptide Research
Get weekly comparison updates, new study alerts, and regulatory changes.
No spam. Unsubscribe anytime.
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.